Ghost Tree Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ghost Tree Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.05M	Buy	+325,000	New	+$731K	0.32%	54
2023 Q4	–	Sell	-215,000	Closed	-$3.3M	–	56
2023 Q3	$3.94M	Sell	215,000 -335,000	-61%	-$7.08M	1.29%	30
2023 Q2	$11.9M	Buy	550,000 +75,000	+16%	+$2.03M	3.92%	9
2023 Q1	$13.9M	Buy	475,000 +125,000	+36%	+$4.34M	4.12%	5
2022 Q4	$12.9M	Sell	350,000 -200,000	-36%	-$7.1M	5.52%	6
2022 Q3	$15.5M	Buy	+550,000	New	+$13.7M	4.35%	6

Other funds holding AMLX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ghost Tree Capital's AMLX Position: Q3 2024 in Review

Ghost Tree Capital opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2024: 325,000 shares worth $1.05M. The stake represents 0.32% of the portfolio and ranks #54 among its holdings. This is a return to the name: Ghost Tree Capital previously reported a position in AMLX as recently as Q3 2023.

Ghost Tree Capital first reported a position in AMLX in Q3 2022 and has held it in 6 quarters since. The position peaked at $15.5M in Q3 2022. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

Ghost Tree Capital held 325,000 shares of Amylyx Pharmaceuticals worth $1.05M as of Q3 2024.
Amylyx Pharmaceuticals was a new Ghost Tree Capital position in Q3 2024.
Amylyx Pharmaceuticals made up 0.32% of Ghost Tree Capital's portfolio in Q3 2024, its #54 holding.
Ghost Tree Capital first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 6 quarters since.
Ghost Tree Capital's Amylyx Pharmaceuticals position peaked at $15.5M in Q3 2022.
110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.